Additionally, neuroblastoma cells can acquire resistance to the BCL-2 inhibitor ABT-737 by upregulating EGFR and develop a dependence on MCL-1, which can be effectively countered by combining erlotinib with a BCL-2 inhibitor [29]. The gene discussed is BCL2; the disease is neuroblastoma.